CXCL16 and neoplasm: Additionally, MDSCs in EC TME can be recruited and activated by cancer cell-derived cytokines/chemokines (IL-6, IGFBP-3, CXCL16, and GM-CSF), thereby accelerating tumor progression by inhibiting CD8+ T cell activation.